Skip to main content

Janus Henderson Horizon Biotechnology Fund

Janus Henderson Horizon Biotechnology Fund is an equity fund managed by Janus Henderson in the Industri – Bioteknologi category.

About this fund

Janus Henderson Horizon Biotechnology Fund is an equity fund run by Janus Henderson, compared against the Industri – Bioteknologi peer group.

Tracking error against its benchmark is 11.3%.

The fund dates from 2018, giving it 8 years of history.

It is run by a team of 3.

The manager states a volatility of 23.4% for the fund.

The reference index is NASDAQ Biotechnology Total Return Index.

Manager
Janus Henderson
Category
Industri – Bioteknologi
Region
Global
Sector
Information Technology
Style
Sector Focus
SFDR
Article 8
ISIN
LU1897414485
Inception
2018-12-10
Benchmark
NASDAQ Biotechnology Total Return Index
AUM
2.1 bn USD

Portfolio managers

Actively managedEquityGlobalTechnology
YTD Return · NOK
–
Calculated NOK return from USD · I (USD) (NOK Calculated)

Computed from NAV history (total return, NOK, to 16 Nov 2026)

Last NAV 40,88 USD · 16 Nov 2026
Fund size
2,1 mrd. USD
Total fund AUM
Management fee
0,75 %
Annual · class I
Ongoing charge
1,24 %
Annual · class I
SFDR
Article 8
Sustainability
Launched
Dec 2018
ISIN LU1897414485
BenchmarkNasdaq Biotechnology · Total return
Fund website
Risk
Volatility (stated by the manager)23,4 %
Sharpe Ratio0,88
Beta1,18
Tracking Error11,3 %
About the fund
The fund

Janus Henderson Horizon Biotechnology Fund has a track record back to 2018. The management company, Janus Henderson Investors, was formed in 2017 through the merger of Janus Capital and Henderson Global Investors. Its headquarters are in London, with a large investment hub in Denver. The company has been privately owned since 30 June 2026 by an investor group led by Trian Fund Management and General Catalyst.

Investment philosophy

The fund aims for long-term capital growth and outperformance of 2% per year, before charges, over any five-year period against the NASDAQ Biotechnology Total Return Index.

The managers

The fund is managed by the Janus Henderson Health Care Team in Denver, led by Andy Acker. He has led the firm's healthcare research since 2007 and joined Janus in 1999. Agustin Mohedas joined the firm in 2019 after working as an analyst at the hedge fund RA Capital, and Daniel Lyons has been a portfolio manager since 2018 and an analyst since 2000. All of the managers combine the roles of analyst and portfolio manager. Lyons holds a PhD in immunology from Stanford, Mohedas holds a Harvard-MIT PhD in medical engineering, and Acker holds an MBA from Harvard Business School.

The portfolio

The portfolio holds many companies, but with a noticeable top weight and a few core positions that recur over time, including Revolution Medicines, Argenx, Vertex Pharmaceuticals, Gilead Sciences and Praxis Precision Medicines. The centre of gravity is in mid-sized companies, with spread into both smaller and larger ones.

FundTelligence description · 18/10/2026
Start date not confirmed — not ranked

Portfolio managers

AG
Portfolio Manager
On the fund since 2023
AN
Portfolio Manager
DA
Portfolio Manager

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data